This post-marketing non-interventional case (H3E-KL-B004, EUDRACT number unknown) concerns a 54 year old 
Asian male. No medical history was reported. Concomitant medications inc  o  -0:  folic acid, vitamin B12 and 
as per the protocol procedures. On 24-Nov-2008, the patient first received pemetrexed 
on day one, intravenously, for the second line treatment of non-smatl cell lung cancer. The last dose of 
study m ion administered prior to the event onset was on the 16-Dec-2008. The patient was hospitalised on an 
unknown date (not reported as a serious event). Ong approximatelyillinweeks since the last dose of 
study medication, the patient experienced the symptom haernoptysis (blood tinged sputum). The event was 
considered to be non-serious and did not lead to the patient's hospitalisation. No laboratory data was provided. 
Unspecified conservative treatment was administered. Following this treatment the atient improved and recovered 
from the event on the 16-Jan-2009. The patient was discharged from hospital o It was not reported 
what action was taken with the study drug or if the event resulted in the permanent discontinuation of the study 
drug. The investigator stated that the event was related to pemetrexed. No assessment of protocol procedures will 
be collected for this trial. Update 08-Apr-2010: Additional information was received from the investigator on 30- 
Print Time: 02-SEP-2014 11:09 AM If a field is blank, there is no data for that field Page 629  of 661 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
Mar-2010, which included downgrade of event of haemoptysis as the investigator considered it to be non-serious 
and did not lead to patient's hospitalisation. Subsequently, this case was determined to be non-valid as there was 
no identifiable serious event. Narrative, corresponding fields and PSUR comments updated accordingly .